Literature DB >> 23053211

Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study.

Evanguelos Xylinas1, Pierre Colin, François Audenet, Véronique Phe, Luc Cormier, Olivier Cussenot, Alain Houlgatte, Gilles Karsenty, Franck Bruyère, Thomas Polguer, Alain Ruffion, Antoine Valeri, François Rozet, Jean-Alexandre Long, Marc Zerbib, Morgan Rouprêt.   

Abstract

OBJECTIVES: To identify predictive factors and assess the impact on oncological outcomes of intravesical recurrence after radical nephroureterectomy (RNU) in upper tract urothelial carcinoma (UTUC).
METHODS: Using a national multicentric retrospective dataset, we identified all patients with UTUC who underwent a RNU between 1995 and 2010 (n = 482). Intravesical recurrence was tested as a prognostic factor for survival through univariable and multivariable Cox regression analysis.
RESULTS: Overall, intravesical recurrence occurred in 169 patients (35 %) with a median age of 69.2 years (IQR: 60-76) and after a median follow-up of 39.5 months (IQR: 25-60). Actuarial intravesical recurrence-free survival estimates at 2 and 5 years after RNU were 72 and 45 %, respectively. On univariable analyses, previous history of bladder tumor, tumor multifocality, laparoscopic approach, pathological T-stage, presence of concomitant CIS and lymphovascular invasion were all associated with intravesical recurrence. On multivariable analysis, previous history of bladder cancer, tumor multifocality and laparoscopic approach remained independent predictors of intravesical recurrence. Existence of intravesical recurrence was not correlated with worst oncological outcomes in terms of disease recurrence (p = 0.075) and cancer-specific mortality (p = 0.06).
CONCLUSIONS: In the current study, intravesical recurrence occurred in 35 % of patients with UTUC after RNU. Previous history of bladder cancer, tumor multifocality, concomitant CIS and laparoscopic approach were independent predictors of intravesical recurrence. These findings are in line with recent published data and should be considered carefully to provide a definitive surveillance protocol regarding management of urothelial carcinomas regardless of the location of urothelial carcinomas in the whole urinary tract.

Entities:  

Mesh:

Year:  2012        PMID: 23053211     DOI: 10.1007/s00345-012-0957-3

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  23 in total

1.  Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy.

Authors:  Jeffery C Wheat; Alon Z Weizer; J Stuart Wolf; Yair Lotan; Mesut Remzi; Vitaly Margulis; Christopher G Wood; Francesco Montorsi; Marco Roscigno; Eiji Kikuchi; Richard Zigeuner; Cord Langner; Christian Bolenz; Theresa M Koppie; Jay D Raman; Mario Fernández; Pierre Karakiewizc; Umberto Capitanio; Karim Bensalah; Jean-Jacques Patard; Shahrokh F Shariat
Journal:  Urol Oncol       Date:  2010-05-06       Impact factor: 3.498

2.  Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma.

Authors:  Michael Rink; Harun Fajkovic; Eugene K Cha; Amit Gupta; Pierre I Karakiewicz; Felix K Chun; Yair Lotan; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2012-01-05       Impact factor: 20.096

3.  Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort.

Authors:  Thomas J Walton; Giacomo Novara; Kazumasa Matsumoto; Wassim Kassouf; Hans-Martin Fritsche; Walter Artibani; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Stephen A Thomas; Vincenzo Ficarra; Maximilian Burger; Stefan Tritschler; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  BJU Int       Date:  2010-11-15       Impact factor: 5.588

Review 4.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

5.  Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma.

Authors:  Enrique Pieras; Guillermo Frontera; Xavi Ruiz; Antoni Vicens; Mariano Ozonas; Pedro Pizá
Journal:  BJU Int       Date:  2010-11       Impact factor: 5.588

6.  Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance.

Authors:  F Rabbani; M Perrotti; P Russo; H W Herr
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

7.  European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update.

Authors:  Morgan Rouprêt; Richard Zigeuner; Juan Palou; Andreas Boehle; Eero Kaasinen; Richard Sylvester; Marko Babjuk; Willem Oosterlinck
Journal:  Eur Urol       Date:  2011-01-14       Impact factor: 20.096

8.  Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients.

Authors:  Wolfgang Otto; Shahrokh F Shariat; Hans-Martin Fritsche; Amit Gupta; Kazumasa Matsumoto; Wassim Kassouf; Guido Martignoni; Thomas J Walton; Stefan Tritschler; Shiro Baba; Patrick J Bastian; Juan I Martínez-Salamanca; Christian Seitz; Armin Pycha; Maximilian Burger; Pierre I Karakiewicz; Vincenzo Ficarra; Giacomo Novara
Journal:  World J Urol       Date:  2011-01-20       Impact factor: 4.226

9.  Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases.

Authors:  Umberto Capitanio; Shahrokh F Shariat; Hendrik Isbarn; Alon Weizer; Mesut Remzi; Marco Roscigno; Eiji Kikuchi; Jay D Raman; Christian Bolenz; Karim Bensalah; Theresa M Koppie; Wassim Kassouf; Mario I Fernández; Philipp Ströbel; Jeffrey Wheat; Richard Zigeuner; Cord Langner; Matthias Waldert; Mototsugu Oya; Charles C Guo; Casey Ng; Francesco Montorsi; Christopher G Wood; Vitaly Margulis; Pierre I Karakiewicz
Journal:  Eur Urol       Date:  2009-04-03       Impact factor: 20.096

10.  Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Evanguelos Xylinas; Michael Rink; Eugene K Cha; Thomas Clozel; Richard K Lee; Harun Fajkovic; Evi Comploj; Giacomo Novara; Vitaly Margulis; Jay D Raman; Yair Lotan; Wassim Kassouf; Hans-Martin Fritsche; Alon Weizer; Juan I Martinez-Salamanca; Kazumasa Matsumoto; Richard Zigeuner; Armin Pycha; Douglas S Scherr; Christian Seitz; Thomas Walton; Quoc-Dien Trinh; Pierre I Karakiewicz; Surena Matin; Francesco Montorsi; Marc Zerbib; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2012-05-04       Impact factor: 20.096

View more
  24 in total

Review 1.  Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.

Authors:  Mounsif Azizi; Salim K Cheriyan; Charles C Peyton; Beat Foerster; Shahrokh F Shariat; Philippe E Spiess
Journal:  Curr Treat Options Oncol       Date:  2019-04-01

2.  Bladder cancer: Tumour recurrence after radical nephroureterectomy for UTUC.

Authors:  Adil Ouzzane; Pierre Colin
Journal:  Nat Rev Urol       Date:  2013-12-17       Impact factor: 14.432

3.  Predictive value of gene methylation for second recurrence following surgical treatment of first bladder recurrence of a primary upper-tract urothelial carcinoma.

Authors:  Bao Guan; Yunchao Xing; Gengyan Xiong; Zhenpeng Cao; Dong Fang; Yifan Li; Yonghao Zhan; Ding Peng; Libo Liu; Xuesong Li; Liqun Zhou
Journal:  Oncol Lett       Date:  2018-04-13       Impact factor: 2.967

4.  Comment on "Durability of response to primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel: OLYMPUS trial final report".

Authors:  Yuxuan Song; Yiqing Du; Caipeng Qin; Tao Xu
Journal:  World J Urol       Date:  2022-02-22       Impact factor: 4.226

5.  Whether diagnostic ureteroscopic biopsy and ureteroscopy without biopsy have different impacts on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy?

Authors:  Yuxuan Song; Jingli Han; Caipeng Qin; Yiqing Du; Tao Xu
Journal:  World J Urol       Date:  2022-05-28       Impact factor: 3.661

6.  UroVysion® predicts intravesical recurrence after radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: a prospective study.

Authors:  Hidehiro Iwata; Naoto Sassa; Masashi Kato; Yota Murase; Shuko Seko; Hideji Kawanishi; Ryohei Hattori; Momokazu Gotoh; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2020-09-21       Impact factor: 3.402

7.  Effect of Preoperative Bacteriuria and Pyuria on Intravesical Recurrence in Patients with Upper Tract Urothelial Carcinoma Undergoing Radical Nephroureterectomy.

Authors:  Hiroshi Fukushima; Masaki Kobayashi; Keizo Kawano; Shinji Morimoto
Journal:  In Vivo       Date:  2017 Nov-Dec       Impact factor: 2.155

Review 8.  Distal ureterectomy techniques in laparoscopic and robot-assisted nephroureterectomy: Updated review.

Authors:  Konstantinos G Stravodimos; Christos Komninos; Ali Riza Kural; Constantinos Constantinides
Journal:  Urol Ann       Date:  2015 Jan-Mar

9.  The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma.

Authors:  Taek Sang Kim; Jeong Hyun Oh; Hyun Yul Rhew
Journal:  J Cancer       Date:  2013-10-05       Impact factor: 4.207

10.  Predictors of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: an inflammation-based prognostic score.

Authors:  Yang Hyun Cho; Young Ho Seo; Seung Jun Chung; Insang Hwang; Ho Song Yu; Sun-Ouck Kim; Seung Il Jung; Taek Won Kang; Dong Deuk Kwon; Kwangsung Park; Jun Eul Hwang; Suk Hee Heo; Geun Soo Kim; Eu Chang Hwang
Journal:  Korean J Urol       Date:  2014-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.